RenovoRx Inc (RNXT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, RenovoRx Inc (RNXT) has a cash flow conversion efficiency ratio of -0.319x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.87 Million) by net assets ($8.98 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is RenovoRx Inc worth for the company's overall valuation and market capitalisation.
RenovoRx Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how RenovoRx Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
RenovoRx Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of RenovoRx Inc ranked by their cash flow conversion efficiency. See how well can RenovoRx Inc service its debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Turker Proje Gayrimenkul Ve Yatirim Gelistirme AS
IS:TURGG
|
-0.003x |
|
EBR Systems Inc
AU:EBR
|
-0.605x |
|
AimCore Technology Co Ltd
TWO:3615
|
0.041x |
|
Sepeda Bersama Indonesia Tbk PT
JK:BIKE
|
-0.079x |
|
Manas Enerji Yonetimi Sanayi & Ticaret AS
IS:MANAS
|
-0.018x |
|
Trias Sentosa Tbk
JK:TRST
|
0.029x |
|
Kellton Tech Solutions Limited
NSE:KELLTONTEC
|
0.001x |
|
Daekyo
KO:019680
|
-0.003x |
Annual Cash Flow Conversion Efficiency for RenovoRx Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of RenovoRx Inc from 2019 to 2025. View current stock price of RenovoRx Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $5.42 Million | $-10.97 Million | -2.024x | +0.68% |
| 2024-12-31 | $4.48 Million | $-9.12 Million | -2.038x | -159.59% |
| 2023-12-31 | $-3.00 Million | $-10.26 Million | 3.419x | +339.17% |
| 2022-12-31 | $6.16 Million | $-8.81 Million | -1.430x | -270.92% |
| 2021-12-31 | $15.35 Million | $-5.92 Million | -0.385x | -260.12% |
| 2020-12-31 | $-14.66 Million | $-3.53 Million | 0.241x | +110.53% |
| 2019-12-31 | $1.47 Million | $-3.35 Million | -2.287x | -- |
About RenovoRx Inc
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded i… Read more